This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.
1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors
ePostersLive by SciGen Technologies S.A. All rights reserved.
September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas
CML - 596
Chronic Myeloid Leukemia (CML)
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with markedly improved survival following the introduction of tyrosine kinase inhibitors.
Despite these advances, hospitalized patients with CML remain vulnerable to infectious complications, organ dysfunction, and multiple medical comorbidities.
Contemporary nationwide data identifying predictors of inpatient mortality among CML hospitalizations remain limited.
We evaluated demographic and clinical predictors of in-hospital mortality among hospitalized patients with CML using a nationally representative U.S. database.
Design: Retrospective cohort study using the National Inpatient Sample (2018–2023).
Population: Adult hospitalizations (≥18 years) with CML identified using ICD-10-CM diagnosis code of C92.
Primary Outcome: In-hospital mortality
Statistical Analysis: Survey-weighted multivariable logistic regression adjusted for: Demographic characteristics, Hospital characteristics, Heart failure, Chronic kidney disease, Diabetes mellitus, Hypertension, COPD, Liver disease, Stroke/TIA, Coronary artery disease, Peripheral arterial disease, Obesity
27,889 CML hospitalizations
Approximately 139,445 weighted hospitalizations nationwide.
Increasing age independently predicted mortality (OR 1.03/year, p<0.001).
Female sex was associated with lower mortality (OR 0.88, p=0.042).
Sepsis was the strongest predictor of inpatient mortality (OR 6.05, p<0.001).
Additional independent predictors included:
Liver disease (OR 2.14)
Stroke/TIA (OR 1.51)
Heart failure (OR 1.48)
COPD (OR 1.17)
Chronic kidney disease and peripheral arterial disease were not significantly associated with mortality.
Diabetes mellitus, hypertension, obesity, and coronary artery disease demonstrated lower adjusted mortality.
Sepsis was the strongest independent predictor of inpatient mortality among hospitalized patients with CML.
Liver disease and cerebrovascular disease substantially increased mortality risk.
Cardiovascular disease, particularly heart failure, remained an important contributor to adverse inpatient outcomes.
Increasing age was associated with progressively higher mortality.
Female sex was independently associated with lower inpatient mortality.
Strengths include a nationally representative sample and survey-weighted multivariable adjustment.
Limitations include reliance on administrative coding and the inability to evaluate laboratory values, disease phase, tyrosine kinase inhibitor use, or treatment timing.
Hospitalized patients with CML remain at significant risk for mortality despite advances in targeted therapy.
Early identification and aggressive treatment of sepsis are essential.
Liver dysfunction and cerebrovascular disease identify patients at particularly high risk.
Comprehensive management of cardiovascular comorbidities may further improve inpatient outcomes.
These findings support multidisciplinary inpatient care and early recognition of systemic complications in hospitalized patients with CML.